Form Health vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 36)
Form Health logo

Form Health

EmergingHealthTech

Virtual Weight Management

Virtual obesity medicine practice with board-certified physicians, dietitians, and coaches; treats obesity as a chronic disease using GLP-1 medications with individualized behavioral plans.

AI VisibilityBeta
Overall Score
D36
Category Rank
#530 of 596
AI Consensus
72%
Trend
stable
Per Platform
ChatGPT
41
Perplexity
33
Gemini
38

About

Form Health is a virtual obesity medicine practice that delivers medically supervised weight loss care through a team-based model pairing board-certified obesity medicine physicians with registered dietitians and health coaches, all accessible through a telehealth platform. The practice treats obesity as a complex chronic disease and develops individualized treatment plans that may include anti-obesity medications — including GLP-1 receptor agonists like semaglutide and tirzepatide — alongside nutritional counseling, behavioral health support, and physical activity guidance based on each patient's medical history, comorbidities, and treatment goals. This multidisciplinary approach mirrors the clinical model of a hospital-based obesity medicine program delivered through a scalable virtual format.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

36
Overall Score
81
#530
Category Rank
#17
72
AI Consensus
71
stable
Trend
stable
41
ChatGPT
80
33
Perplexity
75
38
Gemini
77
31
Claude
86
41
Grok
85

Key Details

Category
Virtual Weight Management
General
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Form Health
Virtual Weight Management

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.